Skip to content

Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19

Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04374617
Enrollment
230
Registered
2020-05-05
Start date
2020-04-01
Completion date
2020-05-01
Last updated
2020-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Critical Illness, Pulmonary Embolism, Pulmonary Embolism and Thrombosis, Sars-CoV2, SARS-CoV Infection, Venous Thromboembolism, Venous Thromboses, Venous Thromboses, Deep, Venous Thrombosis Pulmonary

Brief summary

Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.

Detailed description

SARS-CoV-2 infection has been associated with coagulation disorders and increased risk of venous thromboembolism (VTE). The aim of the study is to determine the cumulative incidence of VTE in critically ill patients with COVID-19 and its impact on prognosis. Methods Cohort study of critically ill patients due to COVID-19. A bilateral venous compression (CUS) ultrasound screening of the lower extremities was performed during a cut-off period in 2 intensive care units of university hospitals in Spain. Asymptomatic and symptomatic VTE were registered: pulmonary embolism (PE) (diagnosed by CT-angiography) and deep venous thrombosis (DVT). The characteristics of the patients, results of their blood tests and their evolution after 7 days of follow-up were recorded.

Interventions

All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with severe COVID-19 pneumonia admitted to the intensive care unit

Exclusion criteria

* Treatment with Extracorporeal membrane oxygenation (ECMO) * Pregnant or postpartum women * Under 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Venous thromboembolisms7 daysPatients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have symptomatic venous thromboembolisms. The remaining patients with positive limb ultrasound or CT-angiography were considered to have asymptomatic venous thrombembolism

Secondary

MeasureTime frameDescription
Deaths7 daysDeaths from all causes during the follow-up

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026